Copyright © 1993 by the European Society of Cardiology.
© 1993 The European Society of Cardiology
Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure
Department of Cardiology, Sint Franciscus Gasthuis Rotterdam, The Netherlands
Received 1 June 1992; revised 12 October 1992; .
Correspondence: Dr F. Hagemeijer, Sint Franciscus Gasthuis, Kleiweg 500, 3045 PM Rotterdam, The Netherlands
Abstract
Calcium sensitization increases myocardial contractility by improving energy utlization of the myocardium, without an increase in intracellular concentrations of cyclic adenosine monophosphate. The calcium sensitizer most extensively studied up to now is pimobendan (UD-CG 115 BS). Vasodilatation results primarily from phosphodiesterase III inhibition
Orally administered pimobendan appears rapidly in plasma. A peak concentration is reached 1.5 h after drug intake; elimination from the plasma compartment has a half-life of 1.5 h. First-pass hepatic O-desmethylation of pimobendan produces the active metabolite UD-CG 212; plasma concentration curves of UD-CG 212 are similar to those of pimobendan, with apeak concentration 1–2 h later than the peak concentration of the parent compound.
In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output. Maintenance doses ofpimobendan are well tolerated and may lead to lasting symptomatic improvement in patients with heart failure; open and blinded trials show that exercise tolerance increases. No attenuation of these effects is seen during long-term therapy with pimobendan.
Patients in chronic congestive heart failure frequently die suddenly; many inotropic agents increase the incidence of sudden death in these patients. Although proarrhythmia has never been observed with pimobendan, arrhythmia suppression with amiodarone seems prudent in heart failure patients receiving maintenance doses of pimobendan.
Key Words: Calcium sensitizer • heart failure • inotropic agent • pharmacology • phosphodiesterase inhibitor • pimobendan • review • sudden death
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Lombard, O. Jons, and C. M. Bussadori Clinical Efficacy of Pimobendan Versus Benazepril for the Treatment of Acquired Atrioventricular Valvular Disease in Dogs J. Am. Anim. Hosp. Assoc., July 1, 2006; 42(4): 249 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Takahashi, Y. Shimazaki, and M. Endoh Decrease in Ca2+-Sensitizing Effect of UD-CG 212 Cl, a Metabolite of Pimobendan, under Acidotic Condition in Canine Ventricular Myocardium J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1060 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Kuriya, S. Ohmori, M. Hino, I. Ishii, H. Nakamura, C. Senda, T. Igarashi, M. Kiuchi, and M. Kitada Identification of Cytochrome P-450 Isoform(s) Responsible for the Metabolism of Pimobendan in Human Liver Microsomes Drug Metab. Dispos., January 1, 2000; 28(1): 73 - 78. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Sata, S. Sugiura, H. Yamashita, H. Fujita, S.-i. Momomura, and T. Serizawa MCI-154 Increases Ca2+ Sensitivity of Reconstituted Thin Filament : A Study Using a Novel In Vitro Motility Assay Technique Circ. Res., April 1, 1995; 76(4): 626 - 633. [Abstract] [Full Text]
|
|